Life Biosciences, a biotech advancing innovative cellular rejuvenation technologies to reverse diseases of aging and injury, has announced preclinical data in nonhuman primates (NHP) for its novel gene therapy candidate which uses a partial epigenetic reprogramming approach to restore visual function.

Revolo Biotherapeutics’ ‘1104 is designed to reset the immune system “upstream” before the inflammatory cascade occurs.

Ikena has seen no proteinuria in monkey trials, and Manfredi reckons others are now following his company in developing subtype-selective Tead inhibitors to get around toxicity; Sporos’s Tead1/4 inhibitor SPRI-0117 appears to be one of these.

Revolo Biotherapeutics thinks it has the data to keep advancing a would-be challenger to Dupixent. In a small, short phase 2a allergy trial, the biotech linked its peptide to a “numeric reduction” on the primary endpoint, emboldening it to start looking forward to further development.

Our lead anti-infective candidate, RECCE® 327 (R327), will be advancing into a Phase Ia/IIb intravenous multiple ascending dose safety and tolerability study and a Phase II clinical trial investigating the efficacy of R327 against diabetic foot ulcer (DFU) infections.

Life Biosciences’ gene therapy platform works by inducing expression of the transcription factors Oct3/4, Sox2 and Klfr4, or OSK—three of the four Yamanaka factors. When all four Yamanaka factors are expressed together, have been shown to fully reprogram differentiated human, mouse and primate cells back into pluripotent stem cells, erasing their cell identity and resetting DNA methylation to an embryonic state.

Shares of MindMed surged Friday morning after researchers who have worked with the company unveiled positive results in a trial using LSD to treat major depressive disorder, running a test similar to the biotech’s trials of its own related compound.

As a ‘smart knee’ that transmits data rolls out, medical specialists and engineers predict sensors will be added to artificial hips, shoulders and spinal implants.